Building upon previous studies in which CAFs were involved in prostate cancer tumorigenesis, our study identifies a subset of innately enzalutamide‐resistant STEAP4+ myoCAF that drive therapy evasion through TFE3‐mediated transcriptional reprogramming. This evidence concerns the gene STEAP4 and prostate cancer.